New drug shows promise for Hard-to-Treat cancers with p53 gene
Disease control
Completed
This study tested a new drug, ALRN-6924, in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments. The study found the dru…
Phase: PHASE1, PHASE2 • Sponsor: Aileron Therapeutics, Inc. • Aim: Disease control
Last updated May 04, 2026 16:29 UTC